Zobrazeno 1 - 10
of 70
pro vyhledávání: '"DAVID, ASHKIN"'
Autor:
Maria A. Mendoza MD, Mohammad H. Alshaer PharmD, PhD, Giovanni Roldan MD, Jose Guillermo Castro MD, David Ashkin MD, Charles A. Peloquin PharmD, Catherine V. Boulanger MD
Publikováno v:
Journal of the International Association of Providers of AIDS Care, Vol 21 (2022)
Background: Tuberculosis (TB) is the leading cause of death in human immunodeficiency virus (HIV)-infected people worldwide. Currently there are no studies examining the use of Rifabutin (RBN) and Dolutegravir (DTG) in co-infected persons. This is a
Externí odkaz:
https://doaj.org/article/31fff5377c7a4841b5fe67945c0a22b7
Autor:
Connie A. Haley, Patricia Macias, Supriya Jasuja, Betsy A. Jones, Marie-Claire Rowlinson, Roshni Jaimon, Pennelyn Onderko, Elaine Darnall, Maria E. Gomez, Charles Peloquin, David Ashkin, Neela D. Goswami
Publikováno v:
Emerging Infectious Diseases, Vol 27, Iss 1, Pp 332-334 (2021)
The US Food and Drug Administration approved a 6-month regimen of pretomanid, bedaquiline, and linezolid for extensively drug-resistant or multidrug-intolerant tuberculosis after a trial in South Africa demonstrated 90% effectiveness 6 months posttre
Externí odkaz:
https://doaj.org/article/d74eb24cd9fc4764bf443d1161ecc1bb
Autor:
Zimy Wansaula, Jonathan M. Wortham, Godwin Mindra, Maryam B. Haddad, Jorge L. Salinas, David Ashkin, Sapna B. Morris, Gail B. Grant, Smita Ghosh, Adam J. Langer
Publikováno v:
Emerging Infectious Diseases, Vol 25, Iss 3, Pp 451-456 (2019)
Mycobacterium bovis bacillus Calmette-Guérin (BCG) is used as a vaccine to protect against disseminated tuberculosis (TB) and as a treatment for bladder cancer. We describe characteristics of US TB patients reported to the National Tuberculosis Surv
Externí odkaz:
https://doaj.org/article/f424a8f4b5154a09a4cbf7beb129b884
Autor:
Sundari R. Mase, Ratima Samron, David Ashkin, Kenneth G. Castro, Stephen Ryan, Barbara Seaworth, Lisa Chen, Alfred Lardizabal, Dawn Tuckey, Amera Khan, Drew L. Posey, Courtney Chappelle, Zelalem Temesgen
Publikováno v:
Journal of Clinical Tuberculosis and Other Mycobacterial Diseases, Vol 17, Iss , Pp - (2019)
Background: Tuberculosis (TB) Regional Training and Medical Consultation Centers (RTMCCs) were established in 2005 for TB medical consultation, training and education in the United States. A medical consultation database (MCD) captured all consultati
Externí odkaz:
https://doaj.org/article/c3daaf4a8d23436285bd872efe06515c
Concomitant Treatment of TB and HCV in Coinfected Patients Using Serum Drug Concentration Monitoring
Publikováno v:
Open Forum Infectious Diseases.
Rationale Concern for drug-drug interactions leading to treatment failure and drug resistant strains have discouraged clinicians from attempting concomitant treatment of hepatitis C (HCV) and Tuberculosis. Increased metabolism of direct-acting antivi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a5dbc594490821741e518e3d2dafea9f
https://doi.org/10.1093/ofid/ofad237
https://doi.org/10.1093/ofid/ofad237
Publikováno v:
New England Journal of Medicine. 387:850-852
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9c73a0ee5f72da7ddbb03f48136d526a
https://doi.org/10.1056/nejmc2119461
https://doi.org/10.1056/nejmc2119461
Autor:
David Ashkin, Pennelyn Onderko, Charles A. Peloquin, Marie-Claire Rowlinson, Patricia Macias, Connie A. Haley, Betsy A. Jones, Roshni Jaimon, Maria E. Gomez, Supriya Jasuja, Neela D. Goswami, Elaine Darnall
Publikováno v:
Emerging Infectious Diseases, Vol 27, Iss 1, Pp 332-334 (2021)
Emerging Infectious Diseases
Emerging Infectious Diseases
The US Food and Drug Administration approved a 6-month regimen of pretomanid, bedaquiline, and linezolid for extensively drug-resistant or multidrug-intolerant tuberculosis after a trial in South Africa demonstrated 90% effectiveness 6 months posttre
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f79f2f02e141e749e62d983c07a84261
https://wwwnc.cdc.gov/eid/article/27/1/20-3766_article
https://wwwnc.cdc.gov/eid/article/27/1/20-3766_article
Autor:
Neela Goswami, Lakshmi Praveena Peddareddy, John Jereb, Angel Colon Semidey, Elaine Darnall, Patricia Macias, Supriya Jasuja, Karen Landers, Shom Dasgupta, Margaret Oxtoby, Christopher Spitters, Lana Dov, Masa Narita, Malini DaSilva, Tracina Cropper, Cricket Gullickson, David Ashkin, Connie Haley
Publikováno v:
Open Forum Infectious Diseases
Background In August 2019 the U.S. FDA approved pretomanid as part of a 6-month all-oral BPaL (bedaquiline, pretomanid, and linezolid) regimen for treating pulmonary extensively drug-resistant (XDR) or treatment-intolerant or nonresponsive multidrug-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3bbc6806a3e968262a2dcf816c6a0c16
http://europepmc.org/articles/PMC8643925
http://europepmc.org/articles/PMC8643925
Publikováno v:
Chest. 160:A330-A331
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e447620baa3be1399d59ffaa4e39b323
https://doi.org/10.1016/j.chest.2021.07.333
https://doi.org/10.1016/j.chest.2021.07.333
Publikováno v:
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 73(9)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::66ea2e7f5991c528508c09956edcf3a4
https://pubmed.ncbi.nlm.nih.gov/33070176
https://pubmed.ncbi.nlm.nih.gov/33070176